- Home
- GTN vs PRTA Comparison
GTN vs PRTA Comparison
Compare GTN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTN | PRTA |
|---|---|---|
| Founded | 1897 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 495.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTN | PRTA |
|---|---|---|
| Price | $4.40 | $9.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $7.60 | ★ $18.86 |
| AVG Volume (30 Days) | ★ 1.2M | 742.4K |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $3,348,000,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | $819.08 |
| P/E Ratio | $11.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.13 | $4.32 |
| 52 Week High | $6.31 | $16.67 |
Technical Indicators
Market Signals| Indicator | GTN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 41.94 |
| Support Level | $4.76 | $8.89 |
| Resistance Level | $4.94 | $9.69 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 0.00 | 30.73 |
Price Performance
Historical ComparisonAbout GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.